drugset / Trial / NCT05731934
The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
Open label, single- and multiple-dose administration, dose-exploratory clinical phase I study to evaluate the safety, tolerability and PK profile of HX301 monolactate capsules in patients with advanced malignant solid tumors and to preliminarily evaluate its antitumor efficacy.
Timeline
- Start
- 2020-09-15
- Primary completion
- 2024-01-12
- Completion
- 2024-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Narazaciclib | Small molecule | 40 mg | Oral |
| Subject | Narazaciclib | Small molecule | 80 mg | Oral |
| Subject | Narazaciclib | Small molecule | 120 mg | Oral |
| Subject | Narazaciclib | Small molecule | 160 mg | Oral |
| Subject | Narazaciclib | Small molecule | 200 mg | Oral |